What were the most practice-changing breast cancer studies and updates presented at ASCO 2026?
In this episode of Breast Friends, Dr. Jason Mouabbi and Dr. Paolo Tarantino share their biggest takeaways from ASCO 2026, discussing the clinical trials, FDA approvals, and emerging therapies they believe will have the greatest impact on breast cancer care.
From HR-positive and HER2-positive disease, to triple-negative breast cancer, the conversation explores how new evidence is changing treatment decisions today—and what clinicians should be watching next.
Topics discussed:
• DESTINY-Breast09 and first-line HER2-positive metastatic breast cancer
• SERENA-6 and ctDNA-guided treatment switching
• OPTIMA and Prosigna-guided chemotherapy de-escalation
• Giredestrant updates
• Gedatolisib and the VIKTORIA-1 trial
• Oral SERDs and the future of endocrine therapy
• ADCs for metastatic triple-negative breast cancer
• Iza-Bren and the PANKU-Breast02 trial
• GLP-1 receptor agonists and breast cancer outcomes
• The NHS-Galleri trial
• Biomarkers, precision oncology, and treatment sequencing
• Looking ahead to ESMO 2026 and SABCS
🎙️ Hosted by Drs. Jason A. Mouabbi & Paolo Tarantino
▶️ Watch on YouTube - https://youtu.be/BZC5_C3KyjE
🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox and Amazon Music - https://linkin.bio/breastfriendspodcast
The Breast Friends Podcast is part of the Community Health Media Podcast Network, where meaningful conversations help patients, caregivers, advocates, and healthcare professionals learn from one another, one story at a time.
#BreastFriends #JasonMouabbi #PaoloTarantino #ASCO2026 #BreastCancer #MedicalOncology #HER2Positive #TripleNegativeBreastCancer #HRPositive #PrecisionOncology #CommunityHealthMedia
